The TETON programme consisted of two replicate, 52-week, randomised, double-blind, placebo-controlled, phase 3 studies, investigating inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis (NCT04708782, NCT05255991). It was a pleasure to talk with Dr. Steven D. Nathan (Inova Fairfax Hospital, Annandale, VA, USA) to discuss the unmet needs in the treatment of IPF and the preclinical evidence supporting the studies investigating inhaled treprostinil in this indication.
The abstract ‘Study Design and Rationale for the TETON Phase 3 Clinical Trials of Inhaled Treprostinil in the Treatment of Idiopathic Pulmonary Fibrosis.’ (Abstract number: PA1934) was presented at ERS 2022, 4–6 September, 2022.
Questions
- What are the unmet needs in the treatment of idiopathic pulmonary fibrosis (IPF)?
- What clinical and preclinical evidence supports the investigation of treprostinil in the treatment of IPF?
Disclosures: Steven Nathan discloses consulting for United Therapeutics; serving on advisory boards for United Therapeutics; receiving honoraria from United Therapeutics; and participating in speaker’s bureaus for United Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
